Bolt Biotherapeutics (BOLT) AI Stock Analysis

• Market Cap: $12.73M
• Dividend Yield: N/A
• Average Volume (3M): 33.44K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.41
• Revenue Growth: -67.87%
• EPS Growth: 0.40%
• Country: US
• Employees: 52
• Sector: Healthcare
• Sector Strength: 55
• Industry: Biotechnology
• EPS (TTM): -5.80
• Shares Outstanding: 1,916,985
• 10 Day Avg. Volume: 30,367
• 30 Day Avg. Volume: 33,442
• PEG Ratio: 0.03
• Price to Book (P/B): 0.28
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.62
• Enterprise Value/Market Cap: 4.86
• Enterprise Value/Revenue: 1.92
• Enterprise Value/Gross Profit: -5.25
• Enterprise Value/Ebitda: -0.23
• 1Y Price Target: $2.00
• Price Target Upside: -69.37% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 5

• Rating: 46 Neutral
• Price Target: $6.00 ▼(-8.12%Downside)

Bolt Biotherapeutics faces significant challenges primarily due to its negative financial performance and valuation metrics. The technical analysis suggests a bearish trend, further impacting the overall score. The lack of earnings call data and corporate events means that these components did not contribute to the score, emphasizing the importance of improving profitability and market momentum.

Positive Factors

Clinical Performance

BDC-4182 outperformed other cytotoxic claudin 18.2 ADCs in preclinical models, suggesting potential competitiveness in the market.

Clinical Progress

BDC-4182 displayed superior efficacy compared to cytotoxic claudin 18.2 ADCs in syngeneic models.

Safety Profile

BDC-3042 has been overall well tolerated with no dose-limiting toxicities and evidence of activity.

Negative Factors

Development Path

BDC-3042's development path will likely require PD-(L)1-based combinations to succeed, pointing to a more challenging development path.

Financial Performance

Bolt reported 4Q24 revenue of $0.0M and EPS of ($0.42), compared to estimates of $0.9M and ($0.34), respectively.

Market Competition

Several peer companies have ongoing or discontinued programs targeting CLDN18.2, indicating a competitive landscape for Bolt Biotherapeutics.

Bolt Biotherapeutics Business Overview & Revenue Model

Company Description

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.

How the Company Makes Money

Bolt Biotherapeutics makes money primarily through the development and commercialization of its proprietary cancer therapies. The company's revenue model includes potential milestone payments and royalties from licensing agreements and partnerships with larger pharmaceutical companies. These collaborations help in the advancement of its drug candidates through clinical trials and regulatory approval processes. Additionally, Bolt may secure funding through equity offerings, grants, or government contracts to support its research and development activities. The company's earnings are influenced by the successful progression and commercialization of its drug pipeline.

Bolt Biotherapeutics Financial Statement Overview

Summary

Bolt Biotherapeutics faces significant profitability challenges despite modest revenue growth. The company maintains a stable balance sheet with low debt but struggles with cash flow inefficiencies. Continued focus on improving operational efficiencies is essential.

Income Statement

Bolt Biotherapeutics shows a modest revenue growth with a 34.3% increase from 2022 to 2023 and a slight decline of 2.4% from 2023 to 2024. However, the company has been experiencing significant losses with a negative net profit margin of -820.7% in 2024. The gross profit margin is stable at 100% for 2024, indicating that cost of goods sold is negligible compared to revenue, but high operational expenses continue to weigh down profitability.

Balance Sheet

The company maintains a relatively low debt-to-equity ratio of 0.44 in 2024, suggesting a conservative leverage approach. However, return on equity remains negative due to consistent losses, indicating inefficiencies in generating returns for shareholders. The equity ratio stands at 57.4%, reflecting a stable financial structure with more than half of its assets funded by equity.

Cash Flow

Operating cash flow remains negative, but improved slightly from -69.5 million in 2023 to -61.3 million in 2024. Free cash flow also increased marginally to -61.3 million, indicating ongoing challenges in cash generation. The operating cash flow to net income ratio of 0.97 suggests that cash flow is closely aligned with net losses, while free cash flow to net income ratio mirrors this trend.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
3.64M	7.69M	7.88M	5.73M	1.26M	231.00K
	Gross Profit
-11.79M	5.51M	5.99M	838.00K	-2.41M	-40.13M
	EBIT
-68.07M	-73.05M	-76.20M	-90.32M	-92.79M	-49.18M
	EBITDA
-61.80M	-66.45M	-74.34M	-88.66M	-91.59M	-48.57M
	Net Income Common Stockholders
-63.35M	-63.12M	-69.20M	-85.88M	-104.39M	-72.27M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
38.84M	47.32M	102.19M	168.89M	186.22M	22.84M
	Total Assets
85.86M	99.63M	159.78M	227.81M	307.72M	46.54M
	Total Debt
24.71M	25.21M	20.22M	22.61M	24.36M	10.88M
	Net Debt
16.32M	18.00M	9.41M	13.37M	-3.03M	5.33M
	Total Liabilities
39.05M	42.43M	47.04M	56.30M	57.60M	151.49M
	Stockholders Equity
46.81M	57.20M	112.74M	171.51M	250.12M	-104.95M
Cash Flow		Free Cash Flow
-57.94M	-61.33M	-69.73M	-78.46M	-59.40M	-50.57M
	Operating Cash Flow
-57.90M	-61.29M	-69.53M	-76.50M	-57.07M	-47.31M
	Investing Cash Flow
61.92M	57.58M	71.04M	57.86M	-232.20M	-20.59M
	Financing Cash Flow
108.00K	108.00K	253.00K	503.00K	311.11M	39.60M

Bolt Biotherapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.53
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BOLT, the sentiment is Negative. The current price of 6.53 is above the 20-day moving average (MA) of 6.31, below the 50-day MA of 6.79, and below the 200-day MA of 10.09, indicating a bearish trend. The MACD of -0.17 indicates Negative momentum. The RSI at 45.83 is Neutral, neither overbought nor oversold. The STOCH value of 58.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BOLT.

Bolt Biotherapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.38B	3.31	-45.11%	3.29%	16.82%	0.04%
CRIS	53 Neutral	$29.29M	―	-2951.24%	―	14.17%	28.26%
BRTX	48 Neutral	$13.58M	―	-117.16%	―	175.03%	55.34%
BOLT	46 Neutral	$12.73M	―	-83.92%	―	-67.87%	0.40%
MEIP	41 Neutral	$15.32M	―	-89.73%	―	-100.00%	-292.59%
CLRB	34 Underperform	$16.86M	―	-208.72%	―	―	56.38%
INAB	34 Underperform	$9.92M	―	-174.66%	―	―	38.53%

Bolt Biotherapeutics Corporate Events

Bolt Biotherapeutics Announces Reverse Stock Split

On June 6, 2025, Bolt Biotherapeutics implemented a one-for-twenty reverse stock split of its common stock, following approval from stockholders and the Board of Directors on May 27, 2025. This move affects the company’s outstanding shares, equity incentive plans, and stock options, with trading on a split-adjusted basis set to begin on June 9, 2025, on the Nasdaq Capital Market under the ticker ‘BOLT’.

The most recent analyst rating on (BOLT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Bolt Biotherapeutics stock, see the BOLT Stock Forecast page.

Bolt Biotherapeutics Announces Reverse Stock Split Approval

On May 27, 2025, Bolt Biotherapeutics‘ Board of Directors approved a one-for-twenty reverse stock split, effective June 6, 2025. This move, intended to consolidate shares and adjust the exercise price of stock options, will see the company’s stock begin trading on a split-adjusted basis on June 9, 2025, under the ticker ‘BOLT’.

The most recent analyst rating on (BOLT) stock is a Hold with a $1.25 price target. To see the full list of analyst forecasts on Bolt Biotherapeutics stock, see the BOLT Stock Forecast page.

Bolt Biotherapeutics Approves Key Governance Changes

On May 27, 2025, Bolt Biotherapeutics held its annual meeting of stockholders, where key decisions were made regarding the company’s governance and financial strategies. During the meeting, two directors were elected to the board, the selection of PricewaterhouseCoopers LLP as the independent auditor for 2025 was ratified, and an amendment for a reverse stock split was approved. These decisions are expected to influence the company’s operational strategies and financial structuring, potentially impacting shareholder value and market perception.

The most recent analyst rating on (BOLT) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Bolt Biotherapeutics stock, see the BOLT Stock Forecast page.